Rapamycin Resistant T Cells and Therapeutic Uses Thereof
Description of Invention:
This invention identified T cell culture conditions that use the immune suppression drug rapamycin (sirolimus) to generate rapamycin-resistant cells having Th1, Th2, Tc1 or Tc2 function (Th=T helper lymphocytes; Tc=cytotoxic T lymphocytes). This invention has demonstrated how to generate T cells enriched for Th1, Th2, Tc1 or Tc2 functions as well as how to control these functions in vivo. Those methods can make T cell therapies significantly more viable and applicable for treatment of a variety of diseases states, including cancer, infectious diseases, autoimmune diseases, Graft vs. Host Disease (GVHD) associated with allogeneic hematopoietic stem cell transplantation, and graft rejection. Thus, this invention has many useful purposes that could generate significant interest among groups pursuing immune therapies, particularly T cell-based therapeutic approaches. Diseases in which T cell based therapies would be of major impact include cancer, viral infections such as HIV disease, autoimmunity, transplantation and any other disease in which the T cells participate.
Inventors:
Drs. Daniel Fowler (NCI) Unsu Jung (NCI) Jeannie Hou (NCI) Ronald Gress (NCI) et al.
Patent Status:
DHHS Reference No. E-063-2003/0 --
U.S. Provisional Application No. 60/478,736 filed 12 Jun 2003
PCT Application No. PCT/US2004/18609 filed 09 Dec 2005, which published as WO 2005/003335 on 13 Jan 2005
U.S. Patent Application No. 11/298,313 filed 09 Dec 2005
Portfolios: Infectious Diseases Cancer
Cancer -Therapeutics-Conventional Chemotherapy-Other Infectious Diseases -Therapeutics-Anti-Viral-AIDS (only) Infectious Diseases -Therapeutics-Anti-Viral-Non-AIDS (only) Cancer -Therapeutics Infectious Diseases -Therapeutics
For Additional Information Please Contact: Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220
